Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference

About this update from Pulse Biosciences, Inc

HAYWARD, Calif. --(BUSINESS WIRE)-- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston . Pulse Biosciences’ Management is scheduled to present on Wednesday, August 13, 2025 , at 11:00 am ET . A live and recorded webcast of the presentation will be available on the “Events Calendar and Presentations” page of the company’s investor website at http://investors.pulsebiosciences.com/ . About Pulse Biosciences ® Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation. Pulse Biosciences , CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA, nanosecond PFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries. View source version on businesswire.com : https://www.businesswire.com/news/home/20250801922238/en/ Investors: Pulse Biosciences, Inc. Jon Skinner , CFO [email protected] Or Gilmartin Group Philip Trip Taylor 415.937.5406 [email protected] Source: Pulse Biosciences, Inc.

View stock analysis, news, and events for Pulse Biosciences, Inc